Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent g1 or g2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL

Blood

Volumn 101, Issue 10, 2003, Pages 4078-4087

  Liu, Qun ^b   Hilsenbeck, Susan ^b   Gazitt, Yair ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 8; CASPASE 9; FAS ANTIGEN; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; APOPTOSIS REGULATORY PROTEIN; CASP8 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CASPASE; CYSTEINE PROTEINASE INHIBITOR; GROWTH INHIBITOR; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORGANOARSENIC DERIVATIVE; OXIDE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; METAPHASE; MYELOMA CELL; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING; WILD TYPE; CELL CULTURE; CELL CYCLE; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; KINETICS; METABOLISM; MITOSIS; MULTIPLE MYELOMA; MUTAGENESIS; PHYSIOLOGY;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARSENICALS; CASPASE 8; CASPASE 9; CASPASES; CELL CYCLE; CYSTEINE PROTEINASE INHIBITORS; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; G1 PHASE; G2 PHASE; GROWTH INHIBITORS; HUMANS; KINETICS; MEMBRANE GLYCOPROTEINS; MITOSIS; MULTIPLE MYELOMA; MUTAGENESIS; OXIDES; POLY(ADP-RIBOSE) POLYMERASES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037772194     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3231     Document Type: Article

References (56)

1. Gregory W, Richards M, Malpas J. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992;10:336-342.
2. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment for multiple myeloma. Blood. 1992;80:887-892.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
4. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.
5. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000;14:262-270.
6. Hu J, Shen ZX, Sun GL, et al. Long-term survival and prognostic study in acute promyelocytic leukemia treated with ATRA, chemotherapy, and As2O3: an experience of 120 patients. Int J Hematol. 1999;70:248-260.
7. Perkins C, Kim CN, Fang G, et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL. Blood. 2000;95:1014-1022.
8. Zhang TC, Cao EH, Li JF, et al. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer. 1999;35:1258-1263.
9. Ora I, Bondesson L, Jonsson C, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun. 2000;277:179-185.
10. Akao Y, Nakagawa Y, Akiyama K, et al. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett. 1999;455:59-62.
11. Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest and induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000;60:3065-3071.
12. Kinjo K, Kizaki M, Muto A, et al. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia. 2000;14:431-438.
13. Rego EM, He LZ, Warrell RP Jr, et al. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc Natl Acad Sci U S A. 2000;97:10173-10178.
14. Shen YL, Zhu Q, Cai X, et al. Multiple mechanisms are involved in differentiation induced by arsenic trioxide in acute promyelocytic leukemia [abstract]. Blood. 2000;96:310a.
15. Shen ZY, Shen J, Cai WJ, et al. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med. 2000;5:155-158.
16. Warrell RP Jr. Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica. 1999;84:75-77.
17. Park JW, Choi YJ, Jang MA, et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun. 2001;6:726-734.
18. Jiang X, Wong B, Yuen S, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer. 2001;93:916-920.
19. Seol JG, Park WH, Kim ES, et al. Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol. 2001;18:249-455.
20. Kitamura K, Minami Y, Yamamoto K, et al. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia. 2000;14:1743-1750.
21. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
22. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687-12690.
23. Marsters SA, Sheridan JP, Donahue CJ, et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κ B. Curr Biol. 1996;6:1669-1676.
24. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-1308.
25. Griffith TS, Chin WA, Jackson GC, et al. Intracellular regulation of APO2/TRAIL-induced apoptosis in human melanoma. J Immunol. 1998;161:2833-2840.
26. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonistic decoy receptor and a death domain containing receptor for APO2/TRAIL. Science. 1997;277:815-818.
27. Sheikh MS, Huang Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/APO2/TRAIL-R3 is a p53 regulated DNA damage inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene. 1999;18:4153-4159.
28. Sheridan JP, Marsters SA, Pitti R.M, et al. Control of APO2/TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-821.
29. Kim K, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to APO2/TRAIL in killing of normal and cancer cells. Clin Cancer Res. 2000;6:335-346.
30. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to APO2/TRAIL receptors 1 and 2 and are essential for apoptosis mediated by APO2/TRAIL receptor 2. Immunity. 2000;12:599-609.
31. Kischkel FC, Lawrence DA, Chuntharapai A, et al. APO2/TRAIL dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000;12:611-620.
32. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis induced by APO2/TRAIL and TNFα in human multiple myeloma cells is not blocked by bcl-2. Cytokine. 1999;11:1010-1019.
33. Gazitt Y. APO2/TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999;13:1817-1824.
34. Liu Q, Gazitt Y. Adenovirus-mediated delivery of p53 results in a substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34+ hematopoietic progenitor cells and normal lymphocytes. Exp Hematol. 2000;28:1354-1362.
35. Kim K, Takimoto R, Gazitt Y, et al. Enhanced APO2/TRAIL sensitivity by p53 overexpression in human cancer but not normal cells. Int J Oncol. 2001;18:241-247.
36. Liu Q, El-Deiry W, Gazitt Y. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp Hematol. 2001;29:962-970.
37. Wu GS, Burns TF, McDonald ER, et al. KILLER/DR5 is a DNA damage-inducible, p53 regulated death receptor gene. Nat Genet. 1997;17:141-143.
38. Nagane M, Pan G, Weddle JJ, et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor related apoptosis inducing ligand in vitro and in vivo. Cancer Res. 2000;60:847-853.
39. Gliniak B, Le T. Tumor necrosis factor-related apoptosis inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 1999;59:6153-6158.
40. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 2000;97:1754-1759.
41. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
42. Gazitt Y, Douer D, Liu Q. The mechanism of arsenic trioxide (ATO, Trisenox)-induced apoptosis: independence of Bcl-2; involvement of G2/M cell cycle arrest and upregulation of surface APO2/TRAIL-receptors [abstract]. Blood. 2001;98:159a.
43. Gazitt Y, Rothenberg ML, Hilsenbeck S, et al. Bcl-2 overexpression is associated with resistance to paclitaxel but not gemcitabine in multiple myeloma cell lines. Int J Oncol. 1998;13:839-848.
44. Mazars G-R, Portier M, Zhang X-G, et al. Mutation of p53 gene in human myeloma cell lines. Oncogene. 1992;7:1015-1018.
45. Tian E, Hu W-X, Gazitt Y. Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines: a study with inducible bcl-2 transfection constructs. Int J Oncol. 1996;9:165-169.
46. Tian E, Gazitt Y. The role of P53, bcl-2 and bax in dexamethasone induced apoptosis in myeloma cell lines. Int J Oncol. 1996;8:719-726.
47. Laska EM, Meisner M, Siegel C. Simple designs and model-free tests for synegy. Biometrics. 1994;50:834-841.
48. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res. 2001;264:56-66.
49. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol. 2002;14:86-91.
50. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000;102:849-862.
51. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20:1803-1815.
52. Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001;61:1645-1651.
53. Mitsiades N, Mitsiades CS, Poulaki V, et al. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 2002;99:2162-2171.
54. Adams JM, Cory S. The bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-1326.
55. Roth W, Reed JC. Apoptosis and cancer: when BAX is TRAILing away. Nat Med. 2002;8:216-218.
56. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res. 2000;60:7149-7155.